Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Seizure, Intellectual disability, and Absent speech; and very common findings: Loss of ambulation. 24 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 14 | Dystonia, Seizure, Ataxia |
Muscles | 6 | Shrinkage of the cerebellum (cerebellar atrophy), Low muscle tone (hypotonia), Weakness of facial musculature |
Head and neck | 1 | Weakness of facial musculature |
Eyes | 1 | Nystagmus |
Digestive system | 1 | Difficulty swallowing (dysphagia) |
IRF2BPL-related disorder is characterized by mild-to-profound developmental delay with or without regression, intellectual disability, seizures, movement disorder (ataxia, dystonia, tremor, parkinsonism), spasticity, and autism spectrum disorder. Feeding issues, gastrointestinal dysmotility, and ophthalmologic manifestations are also reported. Onset is highly variable and can be in the first year of life through the sixth decade. To date, more than 60 individuals have been identified with a pathogenic variant in IRF2BPL. The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Select Features of IRF2BPL-Related Disorder
Feature | % of Persons w/Feature1 | Comment |
|---|---|---|
Developmental delay | 87% | Mild to profound, w/developmental regression in 50% |
Intellectual disability |
IRF2BPL encodes interferon regulatory factor 2 binding protein like (796 aa). Probable E3 ubiquitin protein ligase involved in the proteasome-mediated ubiquitin-dependent degradation of target proteins. Highest expression in Fallopian Tube (105.0 TPM) and Ovary (75.8 TPM).
Neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures is associated with mutations in the IRF2BPL gene on chromosome 14.
IRF2BPL is classified as a druggable target (Transcription Factor category) with score 0.0.
Penetrance for IRF2BPL-related disorder appears to be high; however, substantial intrafamilial and interfamilial variability in age of onset and clinical features has been observed. Developmental delay and intellectual disability were reported in a female with an IRF2BPL pathogenic variant inherited from her apparently unaffected mother who died at age 45 years of an unrelated cause . Possible reduced penetrance has been observed in several additional families [LDM Pena P Marcogliese, personal observations].
Source: GeneReviews — "IRF2BPL-Related Disorder"
IRF2BPL-related disorder should be considered in probands with the following clinical and imaging findings and family history.
Clinical findings in individuals presenting at age 18 years
Source: GeneReviews — "IRF2BPL-Related Disorder"
Because IRF2BPL-related disorder is clinically indistinguishable from many other inherited disorders with similar neurologic findings, diagnosing this condition on clinical grounds only without molecular genetic testing is not feasible. All disorders with neurodevelopmental features and/or ataxia without other distinctive findings should be considered in the differential diagnosis. See:
OMIM Phenotypic Series:
• Autosomal dominant intellectual developmental disorder
• Autosomal recessive intellectual developmental disorder
• Nonsyndromic X-linked intellectual developmental disorder
• Syndromic X-linked intellectual developmental disorder
• Developmental and epileptic encephalopathy
• Hereditary Ataxia Overview
Selected disorders with a high degree of clinical overlap are listed in .
Table 3.
Source: GeneReviews — "IRF2BPL-Related Disorder"
Genetic testing for IRF2BPL is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures. The disease remains an area of unmet medical need.
No clinical practice guidelines for IRF2BPL-related disorder have been published. In the absence of published guidelines, the following recommendations are based on the authors' personal experience managing individuals with this disorder.
To establish the extent of disease and needs in an individual diagnosed with IRF2BPL-related disorder, the evaluations summarized (if not performed as part of the evaluation that led to diagnosis) are recommended.
Table 4.
IRF2BPL-Related Disorder: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Developmental assessment | • To incl motor, adaptive, cognitive, speech-language eval
Eval for early intervention/ special education
For persons age 5 yrs: consider baseline neurocognitive eval
| Neurologic eval | • To incl brain MRI
Consider EEG if seizures are a concern. Note: Abnormal EEG may precede clinical seizures.
Consider dedicated movement disorder eval.
| Physical medicine rehab/ PT OT eval | To incl assessment of:
Gross motor fine motor skills
Contractures
Mobility, ADL, need for adaptive devices
Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills)
| Speech eval | Consider communication device or alternative mode of communication.
Neurobehavioral/
| Neuropsychiatric eval | For persons age 12 mos: screening for concerns incl findings suggestive of ASD, ADHD, ...
Source: GeneReviews — "IRF2BPL-Related Disorder"
View trials for neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Table 6. IRF2BPL-Related Disorder: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Development | Monitor developmental progress educational needs. | At each visit Neurologic |
Ophthalmologic involvement | Dilated eye exam | Per treating ophthalmologist(s) |
Respiratory | Consider PFTs spirometry to assess respiratory complications in those w/progressive neuromuscular compromise. | As needed |
Endocrine | Assess pubertal development | At each visit throughout adolescence |
Family/Community | Assess family need for social work support (e.g., palliative/respite care, home nursing, other local resources), care coordination, or follow-up genetic counseling if new questions arise (e.g., family planning). | At each visit ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; OT = occupational therapy; PFT = pulmonary function test; PT = physical therapy |
Source: GeneReviews — "IRF2BPL-Related Disorder"
Phenotype severity distribution: 3 always present features, 1 very common feature, 5 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures.
11 publications have been identified in PubMed for neurodevelopmental disorder with regression, abnormal movements, loss of speech, and seizures. Research spans Review / Meta-Analysis (45%), Case Report / Case Series (27%), and Basic Science / Preclinical (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 5 | 45% |
Patient case studies | 3 | 27% |
Laboratory research | 2 | 18% |
Disease patterns and progression | 1 | 9% |
Dell'Oca M (2026). [PMID: 41760624](https://pubmed.ncbi.nlm.nih.gov/41760624/). *Nature communications*. [Basic Science / Preclinical]
von Quednow E (2026). [PMID: 41813602](https://pubmed.ncbi.nlm.nih.gov/41813602/). *American journal of medical genetics. Part A*. [Case Report / Case Series]
Alatrash S (2025). [PMID: 40230227](https://pubmed.ncbi.nlm.nih.gov/40230227/). *Journal of movement disorders*. [Case Report / Case Series]
Lou X (2025). [PMID: 40184118](https://pubmed.ncbi.nlm.nih.gov/40184118/). *Medicine*. [Review / Meta-Analysis]
Pascual DM (2025). [PMID: 40377402](https://pubmed.ncbi.nlm.nih.gov/40377402/). *The Biochemical journal*. [Review / Meta-Analysis]
Tanaka T (2025). [PMID: 38767473](https://pubmed.ncbi.nlm.nih.gov/38767473/). *Neural regeneration research*. [Basic Science / Preclinical]
Kristiansen K (2025). [PMID: 39031186](https://pubmed.ncbi.nlm.nih.gov/39031186/). *European child & adolescent psychiatry*. [Review / Meta-Analysis]
Bauersachs D (2024). [PMID: 38903604](https://pubmed.ncbi.nlm.nih.gov/38903604/). *Frontiers in neuroscience*. [Review / Meta-Analysis]
Chen PS (2024). [PMID: 38650104](https://pubmed.ncbi.nlm.nih.gov/38650104/). *Annals of clinical and translational neurology*. [Epidemiology / Natural History]
Read JE (2024). [PMID: 39431640](https://pubmed.ncbi.nlm.nih.gov/39431640/). *Annals of the New York Academy of Sciences*. [Review / Meta-Analysis]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 9:07 AM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
53%
— |
Seizures | 43% | Generalized tonic-clonic (50%), myoclonic (42%), absence (33%), focal tonic-clonic (16%), infantile spasms |
Movement disorder | 40% | Ataxia (30%), dystonia (27%), tremor (13%), parkinsonism (13%); athetosis, chorea, myoclonus are rare. |
Autism spectrum disorder (ASD) | 33% | Autistic features w/o diagnosis of ASD are also reported. |
Feeding/ gastrointestinal issues | 33% | Swallowing difficulties, gastrointestinal dysmotility, feeding intolerance |
Abnormal brain MRI | 23% | Focal or diffuse cortical /or subcortical atrophy, cerebellar brain stem atrophy, thinning/atrophy of corpus callosum |
Joint contractures | 10% | Percentages are from a completed but unpublished clinical study that collected self-reported features in 32 individuals with IRF2BPL-related disorder [LDM Pena, unpublished data; see NCT03892798]. |
Source: GeneReviews — "IRF2BPL-Related Disorder"